Would you consider re-challenging Trastuzumab after resolved grade 2 pneumonitis?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How are you approaching endocrine therapy for patients with metastatic HR+/HER2+ breast cancer in light of enhanced HER2 directed treatment with either T-DXd/pertuzumab or HP/tucatinib?

11 Answers

How would you approach treatment selection for an elderly woman with de novo metastatic HER2+ breast cancer with lung and brain mets?

1 Answers

How, if at all, does the spectrum of HER2 positivity impact efficacy of T-DXd in the frontline setting?

1 Answers

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service